Alumis 2024 net loss $294.2M, cash $288.3M; ACELYRIN merger expected Q2 2025

ALUMIS INC.

Net loss of $294.2M in 2024 vs $155.0M in 2023; R&D expenses rose to $265.6M from $137.7M.
Cash, cash equivalents and marketable securities of $288.3M as of Dec 31, 2024.
All-stock merger with ACELYRIN; pro forma cash ~$737M; Alumis stockholders to own ~55% on diluted basis.
Phase 3 ESK-001 psoriasis topline data expected Q1 2026; Phase 2 MS trial for A-005 to start 2H 2025.
Appointed Jack Danilkowicz as CCO and Sara Klein as CLO to bolster late-stage capabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.